Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Johnson, Lance A ^a,f   Torres, Eileen Ruth S ^a   Impey, Soren ^b,c   Stevens, Jan F ^d,e   Raber, Jacob ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e OREGON STATE UNIVERSITY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ANIMAL; BIOLOGICAL MODEL; BODY WEIGHT; COGNITIVE DEFECT; DISEASE PREDISPOSITION; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; GLUCOSE INTOLERANCE; HIPPOCAMPUS; INSULIN RESISTANCE; LIPID DIET; METABOLISM; METABOLOME; MOUSE; PATHOPHYSIOLOGY; SPATIAL LEARNING; SPATIAL MEMORY;

ANIMALS; APOLIPOPROTEIN E4; BODY WEIGHT; COGNITIVE DYSFUNCTION; DIET, HIGH-FAT; DISEASE SUSCEPTIBILITY; DNA METHYLATION; EPIGENESIS, GENETIC; GENOTYPE; GLUCOSE INTOLERANCE; HIPPOCAMPUS; INSULIN RESISTANCE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; MICE; MODELS, BIOLOGICAL; SPATIAL LEARNING; SPATIAL MEMORY;

EID: 85014959369     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43701     Document Type: Article

References (52)

1. Raber, J., Huang, Y. & Ashford, J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 25, 641-50 (2004).
2. Eisenberg, D. T., Kuzawa, C. W. & Hayes, M. G. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys. Anthropol. 143, 100-11 (2010).
3. Mahley, R. W., Huang, Y. & Weisgraber, K. H. Detrimental effects of apolipoprotein E4: potential therapeutic targets in AD. Curr Alzheimer Res. 4, 537-540 (2007).
4. Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K. & Maeda, N. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 50, S178-S182 (2009).
5. Narayan, K. M., Boyle, J. P., Geiss, L. S., Saaddine, J. B. & Tompson, T. J. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 29, 2114-2116 (2006).
6. Gudala, K., Bansal, D., Schifano, F. & Bhansali, A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 4, 640-50 (2013).
7. Sellbom, K. S. & Gunstad, J. Cognitive function and decline in obesity. J. Alzheimers Dis. 30, S89-S95 (2012).
8. Janson, J., Laedtke, T., Parisi, J. E., O'Brien, P., Petersen, R. C. & Butler, P. C. Increased risk of T2D in Alzheimer disease. Diabetes. 53, 474-81 (2004).
9. Talbot, K. et al. Demonstrated brain insulin resistance in AD patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 122, 1316-38 (2012).
10. Dore, G. A., Elias, M. F., Robbins, M. A., Elias, P. K. & Nagy, Z. Presence of the APOE epsilon4 allele modifes the relationship between T2D and cognitive performance: the Maine-Syracuse Study. Diabetologia. 52, 2551-60 (2009).
11. Peila, R., Rodriguez, B. L. & Launer, L. J. Honolulu-Asia Aging Study. T2D, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 51, 1256-62 (2002).
12. Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101, 284-9 (2004).
13. de la Monte, S. M. Terapeutic targets of brain insulin resistance in sporadic AD. Front Biosci (Elite Ed) 4, 1582-1605 (2012).
14. Hanson, A. J. et al. Diferential Effects of Meal Challenges on Cognition, Metab olism, and Biomarkers for Apolipoprotein E ϵ 4 Carriers and Adults with Mild Cognitive Impairment. J Alzheimers Dis. 48, 205-18 (2015).
15. Convit, A., Wolf, O. T., Tarshish, C. & de Leon, M. J. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100, 2019-22 (2003).
16. Hanson, A. J., Banks, W. A., Hernandez Saucedo, H. & Craf, S. Apolipoprotein E Genotype and Sex Infuence Glucose Tolerance in Older Adults: A Cross-Sectional Study. Dement Geriatr Cogn Dis Extra. 6, 78-89 (2016).
17. Helkala, E. L. et al. Associations between apolipoprotein E phenotype, glucose metabolism and cognitive function in men. An explorative study in a population sample. Diabet Med. 18, 991-7 (2001).
18. Rönn, T. & Ling, C. DNA methylation as a diagnostic and therapeutic target in the battle against T2D. Epigenomics. 7, 451-60 (2015).
19. Feng, J. et al. Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. Nat Neurosci. 18, 536-44 (2015).
20. Impey, S., Pelz, C., Tafessu, A., Marzulla, T., Turker, M. & Raber, J. Proton irradiation Induces Persistent and Tissue-Specific DNA Methylation Changes in the Lef Ventricle and Hippocampus. BMC Genomics. 17, 273 (2016).
21. Chiacchiera, F., Piunti, A. & Pasini, D. Epigenetic methylations and their connections with metabolism. Cell Mol Life Sci. 70, 1495-508 (2013).
22. Johnson, L. A. et al. Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. EBioMedicine. 26, 42 (2015).
23. Kamat, P. K. Streptozotocin induced Alzheimer's disease like changes and the underlying neural degeneration and regeneration mechanism. Neural Regen Res. 10, 1050-1052 (2015).
24. Brands, A. M., Biessels, G. J., de Haan, E. H., Kappelle, L. J. & Kessels, R. P. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care. 3, 726-735 (2005).
25. Ruis, C., Biessels, G. J., Gorter, K. J., van den Donk, M., Kappelle, L. J. & Rutten, G. E. Cognition in the early stage of type 2 diabetes. Diabetes Care. 7, 1261-1265 (2009).
26. Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., Greicius, M. D. & Neuroimaging, A. D. Initiative. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain. 138, 3734-46 (2015).
27. Ong, Q. R., Chan, E. S., Lim, M. L., Cole, G. M. & Wong, B. S. Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci Rep. 4, 3754 (2014).
28. Perkins, M. et al. A ltered Energ y Met ab olism Pathways in the Posterior Cingulate in Young Adult Ap olip oprotein E ϵ 4 C arriers. J. Alzheimers Dis. 53, 95-106 (2016).
29. Hanson, A. J., Craf, S. & Banks, W. A. The APOE genotype: modification of therapeutic responses in AD. Curr Pharm Des. 21, 114-20 (2015).
30. Maioli, S. et al. Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. J Alzheimers Dis. 32, 341-55 (2012).
31. To, A. W., Ribe, E. M., C huang, T. T., S chroeder, J. E. & L ovestone, S.Te ϵ 3 and ϵ 4 alleles of human APOE diferentially afect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One. 6, e16991 (2011).
32. Sanchez-Mut, J. V. & Gräf, J. Epigenetic Alterations in AD. Front Behav Neurosci. 9, 347 (2015).
33. Münzel, M. et al. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl. 49, 5375-7 (2010).
34. Kanoski, S. E. & Davidson, T. L. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol. Behav. 103, 59-68 (2011).
35. Ansoleaga, B. et al. Deregulation of purine metabolism in AD. Neurobiol Aging. 36, 68-80 (2015).
36. Kaddurah-Daouk, R. et al. Pharmacometabolomics Research Network. Alterations in metabolic pathways and networks in AD. Transl. Psychiatr. 3, e244 (2013).
37. Sims, B., Powers, R. E., Sabina, R. L. & Teibert, A. B. Elevated adenosine monophosphate deaminase activity in AD brain. Neurobiol Aging. 19, 385-91 (1998).
38. Hakim, A. M., Moss, G. & Gollomp, S. M. The effect of hypoxia on the pentose phosphate pathway in brain. J Neurochem. 26, 683-688 (1976).
39. del Castillo, Velasco-Martínez I, Hernández-Camacho, C. J., Méndez-Rodríguez, L. C. & Zenteno-Savín, T. Purine metabolism in response to hypoxic conditions associated with breath-hold diving and exercise in erythrocytes and plasma from bottlenose dolphins (Tursiops truncatus). Comp. Biochem. Physiol. A Mol. Integr. Physiol. 191, 196-201 (2016).
40. Zlokovic, B. V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 70, 440-4 (2013).
41. Dumanis, S. B., DiBattista, A. M., Miessau, M., Moussa, C. E. & Rebeck, G. W. APOE genotype afects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem. 124, 4-14 (2013).
42. Chen, Y., Durakoglugil, M. S., Xian, X. & Herz, J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA 107, 12011-6 (2010).
43. Martins, R. N., Harper, C. G., Stokes, G. B. & Masters, C. L. Increased cerebral glucose-6-phosphate dehydrogenase activity in AD may refect oxidative stress. J. Neurochem. 46, 1042-1045 (1986).
44. Palmer, A. M. The activity of the pentose phosphate pathway is increased in response to oxidative stress in AD. J. Neural Transm. 106, 317-28 (1999).
45. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
46. Vaishnavi, S. N., Vlassenko, A. G., Rundle, M. M., Snyder, A. Z., Mintun, M. A. & Raichle, M. E. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA 107, 17757-62 (2010).
47. Vlassenko, A. G. et al. Spatial correlation between brain aerobic glycolysis and A-beta deposition. Proc Natl Acad Sci USA 41, 17763-17767 (2010).
48. Orešič, M. et al. Metabolome in progression to AD. Transl. Psychiatry. 1, e57 (2011).
49. Arbones-Mainar, J. M. et al. Metabolic shifs toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4. Int. J. Obes. 40, 1574-1581 (2016).
50. Knouf, C., Hinsdale, M. E., Mezdour, H., Altenburg, M. K., Watanabe, M., Quarfordt, S. H., Sullivan, P. M. & Maeda, N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579-86 (1999).
51. Kirkwood, J. S., Maier, C. & Stevens, J. F.Simultaneous, untargeted metabolic profling of polar and nonpolar metabolites by LC-Q-TOF mass spectrometry. Curr. Protoc. Toxicol. 4, 39 (2013).
52. Xia, J. & Wishart, D. S. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 26, 2342-2344 (2010).